The DOI matches its Crossref record; 443 of the 443 references it cites were found in a registry or an index.
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Open accessAbstract
BACKGROUND: Researchers have suggested that omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) benefit cardiovascular health. Guidelines recommend increasing omega-3-rich foods, and sometimes supplementation, but recent trials have not confirmed this. OBJECTIVES: To assess effects of increased intake of fish- and plant-based omega-3 for all-cause mortality, cardiovascular (CVD) events, adiposity and lipids. SEARCH METHODS: We searched CENTRAL, MEDLINE and Embase to April 2017, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to September 2016, with no language restrictions. We handsearched systematic review references and bibliographies and contacted authors. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation and/or advice to increase LCn3 or ALA intake versus usual or lower intake. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion, extracted data and assessed validity. We performed separate random-effects meta-analysis for ALA and LCn3 interventions, and assessed dose-response relationships through meta-regression. MAIN RESULTS: We included 79 RCTs (112,059 participants) in this review update and found that 25 were at low summary risk of bias. Trials were of 12 to 72 months' duration and included adults at varying cardiovascular risk, mainly in high-income countries. Most studies assessed LCn3 supplementation with capsules, but some used LCn3- or ALA-rich or enriched foods or dietary advice compared to placebo or usual diet. LCn3 doses ranged from 0.5g/d LCn3 to > 5 g/d (16 RCTs gave at least 3g/d LCn3).Meta-analysis and sensitivity analyses suggested little or no effect of increasing LCn3 on all-cause mortality (RR 0.98, 95% CI 0.90 to 1.03, 92,653 participants; 8189 deaths in 39 trials, high-quality evidence), cardiovascular mortality (RR 0.95, 95% CI 0.87 to 1.03, 67,772 participants; 4544 CVD deaths in 25 RCTs), cardiovascular events (RR 0.99, 95% CI 0.94 to 1.04, 90,378 participants; 14,737 people experienced events in 38 trials, high-quality evidence), coronary heart disease (CHD) mortality (RR 0.93, 95% CI 0.79 to 1.09, 73,491 participants; 1596 CHD deaths in 21 RCTs), stroke (RR 1.06, 95% CI 0.96 to 1.16, 89,358 participants; 1822 strokes in 28 trials) or arrhythmia (RR 0.97, 95% CI 0.90 to 1.05, 53,796 participants; 3788 people experienced arrhythmia in 28 RCTs). There was a suggestion that LCn3 reduced CHD events (RR 0.93, 95% CI 0.88 to 0.97, 84,301 participants; 5469 people experienced CHD events in 28 RCTs); however, this was not maintained in sensitivity analyses - LCn3 probably makes little or no difference to CHD event risk. All evidence was of moderate GRADE quality, except as noted.Increasing ALA intake probably makes little or no difference to all-cause mortality (RR 1.01, 95% CI 0.84 to 1.20, 19,327 participants; 459 deaths, 5 RCTs),cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25, 18,619 participants; 219 cardiovascular deaths, 4 RCTs), and CHD mortality (1.1% to 1.0%, RR 0.95, 95% CI 0.72 to 1.26, 18,353 participants; 193 CHD deaths, 3 RCTs) and ALA may make little or no difference to CHD events (RR 1.00, 95% CI 0.80 to 1.22, 19,061 participants, 397 CHD events, 4 RCTs, low-quality evidence). However, increased ALA may slightly reduce risk of cardiovascular events (from 4.8% to 4.7%, RR 0.95, 95% CI 0.83 to 1.07, 19,327 participants; 884 CVD events, 5 RCTs, low-quality evidence with greater effects in trials at low summary risk of bias), and probably reduces risk of arrhythmia (3.3% to 2.6%, RR 0.79, 95% CI 0.57 to 1.10, 4,837 participants; 141 events, 1 RCT). Effects on stroke are unclear.Sensitivity analysis retaining only trials at low summary risk of bias moved effect sizes towards the null (RR 1.0) for all LCn3 primary outcomes except arrhythmias, but for most ALA outcomes, effect sizes moved to suggest protection. LCn3 funnel plots suggested that adding in missing studies/results would move effect sizes towards null for most primary outcomes. There were no dose or duration effects in subgrouping or meta-regression.There was no evidence that increasing LCn3 or ALA altered serious adverse events, adiposity or lipids, except LCn3 reduced triglycerides by ˜15% in a dose-dependant way (high-quality evidence). AUTHORS' CONCLUSIONS: This is the most extensive systematic assessment of effects of omega-3 fats on cardiovascular health to date. Moderate- and high-quality evidence suggests that increasing EPA and DHA has little or no effect on mortality or cardiovascular health (evidence mainly from supplement trials). Previous suggestions of benefits from EPA and DHA supplements appear to spring from trials with higher risk of bias. Low-quality evidence suggests ALA may sli
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–443 of 443
(2005) · BMJ · doi:10.1136/bmj.331.7511.266 · Cited by 10
Selvais, P. L. (1995) · Diabetologia · doi:10.1007/bf00400104 · Cited by 9
n-3 Fatty Acids and Retinal Function
Dangour, A. D., Allen, E., Elbourne, D. R., FLETCHER, A. E., Neveu, M. M., Uauy, R. D., & Holder, G. E. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.043 · Cited by 9
Caldwell, S. H., Argo, C. K., Henry, T. D., Lackner, C., Pramoonjago, P., WELTMAN, A. L., de Lange, E. E., Al-Osaimi, A. M., Shah, N., Simmons-Egolf, W. D., et al. (2011) · Journal of Hepatology · doi:10.1016/s0168-8278(11)60019-6 · Cited by 9
Clough, G. F., McCormick, K. G., Scorletti, E., Bhatia, L. S., Calder, P. C., Griffin, M. J., & Byrne, C. D. (2016) · Diabetologia · doi:10.1007/s00125-016-3966-8 · Cited by 9
[Long-term effects of low dosage fish oil on serum lipids and lipoproteins].
Franzen, D., Geisel, J., Höpp, H. W., Oette, K., & Hilger, H. H. (1993) · PubMed · Cited by 9
Does a Daily Walnut Supplement Given for a Year Result in Body Weight Gain?
Bitok, E., Rajaram, S., Ros, E., Kazzi, N., Huey, L., Jaceldo‐Siegl, K., Juma, D., Cofán, M., Calvo, C., & Sabaté, J. (2016) · The FASEB Journal · doi:10.1096/fasebj.30.1_supplement.1157.5 · Cited by 8
Dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus
Brown, T., Song, F., Wang, X., Brainard, J., & Hooper, L. (2017) · UEA Digital Repository (University of East Anglia) · Cited by 8
Self-citationPlasma Omega-3 Fatty Acids Before and After Nutritional Therapy
NYG, J. K. G. H. B. (1998) · Journal of Nutritional & Environmental Medicine · doi:10.1080/13590849862276 · Cited by 7
Chew, E. Y., & Clemons, T. E. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2009 · Cited by 7
Eritsland, J., Seljeflot, I., Arnesen, H., & Abdelnoor, M. (1992) · Thrombosis Research · doi:10.1016/0049-3848(92)90464-l · Cited by 7
Towards evidence-based practice via practice-based evidence: the Italian experience
Visentin, G., & on behalf of Risk and Prevention Study Group (2008) · Family Practice · doi:10.1093/fampra/cmn079 · Cited by 7
Nigam, A., Talajic, M. R., Roy, D., Nattel, S., Lambert, J., Nozza, A., Jones, P., O’Hara, G. E., Kopecky, S. L., Brophy, J. M., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.658 · Cited by 7
[The effect of unsaturated fatty acids on the incidence of coronary infarction, etc].
Natvig, H. (1967) · PubMed · Cited by 7
DT‐01‐01: MAPT (multi‐domain Alzheimer's prevention trial): Results at 36 months
Vellas, B. J., Carrié, I., Guyonnet, S., Touchon, J., DANTOINE, T. F., Dartigues, J., Cufi, M.-N., Bordes, S., Gasnier, Y., Robert, P. H., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.08.151 · Cited by 7
Effects of supplementary dietary polyunsaturated fat on cancer incidence
Hanson, S. (2017) · UEA Digital Repository (University of East Anglia) · doi:10.13140/rg.2.2.16002.48320 · Cited by 7
Alekseeva, R. I., KhKh, S., Плотникова, О. А., Meshcheriakova, V. A., Mal'tsev, G. I., & Sn, K. (2000) · PubMed · Cited by 6
Eicosapentaenoic Acid as the Gold Standard for Patients With Peripheral Artery Disease?
Yamanouchi, D., & Komori, K. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0449 · Cited by 6
Engell, R. E., Sanman, E., Lim, S. S., & Mozaffarian, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61299-4 · Cited by 5
Scorletti, E., Bhatia, L. S., McCormick, K. G., Clough, G. F., Nash, K. L., Calder, P. C., & Byrne, C. D. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.04.004 · Cited by 5
P3‐419: The LipiDiDiet study: Rationale and study design
Freund‐Levi, Y., Visser, P. J., Kivipelto, M., Wieggers, R. L., Hartmann, T., & Soininen, H. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2093 · Cited by 5
Omega-3 Fatty Acids Improve Dyslipidemia But Not Inflammatory Markers in Metabolic Syndrome
Gill, E. A., Chen, M. A., Thirumalai, A., Fish, B. E., & Paramsothy, P. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.04.055 · Cited by 5
Hill, C. L., Lester, S. E., & Jones, G. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208781 · Cited by 5
Effect of dietary restriction and n‐3PUFA supplementation on insulin resistance in obese adults
Tapsell, L. C., Batterham, M. J., & Charlton, K. E. (2010) · The FASEB Journal · doi:10.1096/fasebj.24.1_supplement.733.9 · Cited by 5
Maggioni, A. P., Fabbri, G., Bosch, J., Dyal, L., Rydén, L., Gerstein, H. C., Yusuf, S., & ORIGIN Investigators (2013) · European Heart Journal · doi:10.1093/eurheartj/eht308.1966 · Cited by 5
PP128-SUN EFFECT OF OMEGA 3 FATTY ACIDS IN PATIENTS WITH HYPERTENSION AND ATRIAL FIBRILLATION
SIANNI, A., Matsoukis, I. L., GANOTOPOULOU, A., Paraskevas, P. G., Asimis, A., Tsivilis, N., & Liouris, I. (2013) · Clinical Nutrition · doi:10.1016/s0261-5614(13)60173-9 · Cited by 5
Pogozheva, A. V., Rozanova, I. A., Sorokovoĭ, K. V., Karagodina, Z. V., & Mm, L. (1997) · PubMed · Cited by 5
Gazsó, A., Horrobin, D. F., & Sinzinger, H. (1992) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7262-1_20 · Cited by 5
Zinger, P., Berger, I., Liuk, K., Taube, K., & Naumann, E. (1987) · PubMed · Cited by 5
Pogozheva, A. V., Tutel'ian, V. A., Гаппарова, К. М., Ēn, T., & Miagkova, M. A. (2000) · PubMed · Cited by 5
Junker, L., Engel, S., Berger, I., & Barleben, H. (1990) · PubMed · Cited by 5
[Total lipid content in the blood after using fish oil in natural and emulsified forms].
Bv, K., Zhoglo, F. A., & Zaverbnyĭ, M. I. (1977) · PubMed · Cited by 5
From pies to pilchards: dietary assistants increase consumption of oil rich fish
Harrison, R., & Elton, P. (2000) · Research Explorer (The University of Manchester) · Cited by 5
Rationale and design of a clinical trial on N-3 fatty acids and cardiac arrhythmia (SOFA)
Brouwer, I. A., Katan, M., Schouten, E. G., Camm, A. J., Böcker, D., Hauer, R. N. W., WEVER, E. F. D., Oosterwijk, C., & Zock, P. L. (2001) · Socio-Environmental Systems Modeling · Cited by 5
Hoogeveen, E., Gemen, E., Geleijnse, J. M., Kusters, R., Kromhout, D., & Giltay, E. (2012) · Data Archiving and Networked Services (DANS) · Cited by 5
Soininen, H. S., Visser, P. J., Kivipelto, M., van Hees, A. M. J., Rouws, C., & Hartmann, T. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.108 · Cited by 4
[Development of toxicological test methods: possibilities and limitations].
Gapparova, K. M., Pogozheva, A. V., Sn, K., & Tutel'ian, V. A. (2000) · PubMed · Cited by 4
Leng, G. C. (1997) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/s0952-3278(97)90137-x · Cited by 4
Zhang, Q., O’Shea, J. E., Thorne, R., Tapsell, L. C., Batterham, M. J., & Charlton, K. E. (2010) · Research Online (University of Wollongong) · Cited by 3
Fonollá, J., Díaz-Ropero, M. P., Geerlings, A., Marti, J., & López‐Huertas, E. (2010) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(10)70266-x · Cited by 3
Tatsuno, I., Saito, Y., Kudou, K., Otake, J., & Minamide, Y. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht309.p4185 · Cited by 3
Lakshminarayan, D., Elajami, T. K., Soliman, M. Y., Alfaddagh, A., & Welty, F. K. (2015) · Circulation · doi:10.1161/circ.132.suppl_3.15530 · Cited by 3
Visser, P. J., Soininen, H. S., Kivipelto, M., Freund‐Levi, Y., Kamphuis, P. J. G. H., Wieggers, R. L., & Hartmann, T. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1381 · Cited by 2
Research works printed but not linked: 83
- Geleijnse, 2011, Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 1, S512, 10.1016/j.jalz.2011.05.1432 · DOI
- Brouwer, 2013, Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the alpha omega trial, PLOS ONE, 8, e81519, 10.1371/journal.pone.0081519 · DOI
- Eussen, 2012, Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction, European Heart Journal, 33, 1582, 10.1093/eurheartj/ehr499 · DOI
- Geleijnse, 2011, Effects of n-3 fatty acids on cognitive decline: A randomized double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 1, S512, 10.1016/j.jalz.2011.05.1432 · DOI
- Geleijnse, 2012, Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients, Alzheimer's & Dementia, 8, 278, 10.1016/j.jalz.2011.06.002 · DOI
- Geleijnse, 2010, Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial, American Heart Journal, 159, 539, 10.1016/j.ahj.2009.12.033 · DOI
- Giltay, 2012, No effects of n-3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial, International Journal of Andrology, 35, 680, 10.1111/j.1365-2605.2012.01255.x · DOI
- Giltay, 2011, Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction, American Journal of Clinical Nutrition, 94, 1442, 10.3945/ajcn.111.018259 · DOI
- Hoogeveen, 2012, Effects of N-3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial, Nephrology Dialysis Transplantation, 27, ii64
- Hoogeveen, 2014, No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial, European Journal of Preventive Cardiology, 21, 1429, 10.1177/2047487313494295 · DOI
- Hoogeveen, 2014, Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial, Clinical Journal of The American Society of Nephrology: CJASN, 9, 1676, 10.2215/CJN.10441013 · DOI
- Kromhout, 2011, N-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes, Diabetes Care, 34, 2515, 10.2337/dc11-0896 · DOI
- Kromhout, 2010, N-3 fatty acids and cardiovascular events after myocardial infarction, New England Journal of Medicine, 363, 2015, 10.1056/NEJMoa1003603 · DOI · Paper page
- Burr, 1989, Fish and the heart, Lancet, ii, 1451
- Harrison, 2005, Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]
- Harrison, 2003, Using community-based dietary assistants to increase the intake of oil-rich fish among older people, European Journal of Public Health, 13, 105
- Doi, 2014, Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome, European Heart Journal, 35, 1156
- Feagan, 2008, Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials, JAMA, 229, 1690, 10.1001/jama.299.14.1690 · DOI · Paper page
- Erdogan, 2007, Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion, Heart Rhythm, 4, S185
- Edel, 2013, Flaxseed lignan metabolites elicit antihypertensive effects in pad patients in the flax-pad trial, Annals of Nutrition and Metabolism, 63, 1339
- Pierce, 2014, The use of dietary flaxseed to promote cardiovascular health, Acta Physiologica, 211, 15
- Pierce, 2013, The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease, Cardiology (Switzerland), 126, 201
- Gill, 2014, Omega-3 fatty acids effects on carotid IMT in metabolic syndrome, Circulation, 130, A1269. Abstract
- Finzi, 2009, Antiarrhythmic effects of n-3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI-HF trial, European Heart Journal, 30, 279
- Rovere, 2011, Effect of n-3PUFA on heart rate variability. Data from the GISSI-HF holter substudy, Circulation, 124, A14829
- Latini, 2011, Circulating levels of n-3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI-HF trial, European Heart Journal, 32, 919
- Marchioli, 2009, Time course analysis of the effect of n-3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI-HF trial, European Heart Journal, 30, 165
- Marchioli, 2009, Time course analysis of the effect of n-3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI-HF trial, European Heart Journal, 30, 432
- Marchioli, 2009, Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI-Heart failure Trial, European Heart Journal, 30, 1026
- Marchioli, 2009, Effect of n-3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI-heart failure trial, European Heart Journal, 30, 426
- Marchioli, 2009, Effect of n-3 PUFA according to fish intake: preliminary results of GISSI-Heart Failure, European Heart Journal, 30, 707
- Tan, 2010, Dietary Manipulation and Weight Management [PhD thesis]
- Delrieu, 2011, Multidomain alzheimer's disease preventive trial: florbetapir ancillary study, Alzheimer's and Dementia, 1, S419, 10.1016/j.jalz.2011.05.1217 · DOI
- Gillette, 2009, The multidomain Alzheimer preventive trial (MAPT): a new approach for the prevention of Alzheimer's disease, Alzheimer's & Dementia, S4-02-05, 145, 10.1016/j.jalz.2009.05.496 · DOI
- Gillette-Guyonnet, 2011, MAPT study: a 3-year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects-rationale, design and baseline data, Alzheimer's & Dementia, 1, S97
- Vellas, 2012, MAPT (multidomain Alzheimer preventive trial) imaging (MRI, FDG-PET, amyloid-PET) data, Journal of Nutrition, Health and Aging, 16, 812
- Pinto, 2015, Effect of low doses of long chain n-3 PUFA intake on daytime heart rate variability: results from the MARINA study, European Journal of Preventive Cardiology, 1, S146
- Nodari, 2010, Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients, European Heart Journal, 31, 850
- Nodari, 2012, Plasma levels of n-3 polyunsaturated fatty acids and risk of hospitalization in patients with non-ischemic cardiomyopathy, Circulation. Conference: American Heart Association, 126, A17431
- Ilsey, 1987, Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty, Australian & New Zealand Journal of Medicine, 17, 559
- Naesgaard, 2014, The effect on vitamin D levels of long-term high-dose treatment with a concentrated omega-3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction, Circulation, 130, A17245
- Poenitz, 2012, Pentraxin 3 is uninfluenced by high doses of concentrated omega-3 fatty acids administered for 12 months following an acute myocardial infarction, Circulation. Conference: American Heart Association, 126, A13464
- Bordeleau, 2013, Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial, Diabetes, 62, A72
- Proudman, 2012, Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose, Internal Medicine Journal, 42, 2
- Eritsland, 1994, Effect of supplementation with n-3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study, European Heart Journal, 15, 29
- Eritsland, 1993, Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids, Thrombosis and Haemostasis, 69, 1065
- Galan, 2008, The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics, Trials, 9, 35, 10.1186/1745-6215-9-35 · DOI
- Galan, 2009, The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events, Sang Thrombose Vaisseaux, 21, 207
- Galan, 2009, The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events, Sang Thrombose Vaisseaux, 21, 207
- McCormick, 2015, Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n-3 fatty acids, Diabetic Medicine, 32, 99
- Scorletti, 2014, Potential benefits of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study, Diabetic Medicine, 31, 1
- Baleztena Gurrea, 2015, Utility of heavy food supplement in omega-3 fatty acids in the prevention of dementia, in relation to the basal nutritional level, in people of advanced age: randomized multicenter study, Revista Española de Geriatría y Gerontología, 50, 1
- Bes-Rastrollo, 2015, Utility of a rich food supplement Omega-3 fatty acids in the prevention of dementia, in relation to baseline nutritional level, in people with advanced age: multicentre randomised study, Nutrición Clínica en Medicina, 9, 38
- Cheng, 1990, The effect of omega-3 fatty acids on restenosis after coronary angioplasty, European Heart Journal, 11, 368
- Fonolla, 2011, Daily intake of a low lactose dairy drink enriched with omega-3 (EPA+DHA), oleic acid and calcium improves nutritional and bone status in healthy postmenopausal women, Clinical Nutrition, 6, 86
- Franzen, 1989, Long-term effect of fish oil and olive oil on plasma lipids in patients with CHD, Zeitschrift fur Kardiologie, 78, 28
- Gapparova, 2000, Effects of omega-3 polyunsaturated fatty acids of vegetable and animal origin on clinical and metabolic indicators and the intensity of lipid peroxidation in patients with ischemic heart disease and impaired carbohydrate tolerance, Voprosy Pitaniia, 69, 46
- Hashimoto, 2011, Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function in elderly people with very mild dementia in Japan, Alzheimer's and Dementia, 1, S610
- Hashimoto, 2012, Beneficial effects of daily dietary omega-3 polyunsaturated fatty acid supplementation on age related cognitive decline in elderly Japanese with very mild dementia: a 2-year randomized,double-blind, placebo-controlled trial, Journal of Aging Research & Clinical Practice, 1, 193
- Lau, 1991, Effects of Maxepa on non-steroidal anti-inflammatory drug useage in patients with mild rheumatoid arthritis, British Journal of Rheumatology, 30, 137
- Lorgeril, 1999, Does a Mediterranean dietary pattern prolong survival?, Cardiology Review, 16, 30
- Mantzaris, 1996, A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis, Hellenic Journal of Gastroenterology, 9, 138
- Mate, 1991, Does dietary fish oil maintain the remission of Crohn's disease: a study case control, Gastroenterology, 100, A228
- Colquhoun, 1997, Rationale and design of the "OLIVE" study (comparison of an olive oil enriched to a low fat diet intervention study using vascular endpoints), Atheroscerosis, 134, 326
- Colquhoun, 1998, Comparison of an olive oil enriched diet to a low fat diet intervention study using vascular endpoints: assessed by repeat quantitative angiography (OLIVE study), Australian Journal of Nutrition and Dietetics, 55, S24
- Meilahn, 1990, Coagulation parameters among healthy adults taking fish oil versus placebo, Arteriosclerosis, 10, 916A
- Singh, 2012, Effect of low W-6/W-3 fatty acid ratio Paleolithic style diet in patients with acute coronary syndromes: a randomized, single blind, controlled trial, World Heart Journal, 4, 71
- Singh, 1997, Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4, Cardiovascular Drugs and Therapy, 11, 485, 10.1023/A:1007757724505 · DOI · Paper page
- Bowman, 2012, ASCEND: design and baseline characteristics of a large randomised trial in diabetes, Diabetes, 61, A556
- Chandrakala, 2012, Low-fat (< 20%) diets prevent type 2 diabetes mellitus, Diabetes, 61, A190
- Laake, 2014, Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study, BMC Geriatrics, 14, 74, 10.1186/1471-2318-14-74 · DOI
- Shinto, 2015, Omega 3 fatty acids for the prevention of vascular cognitive aging: methods and rationale for a phase II trial, Alzheimer's & Dementia, 11, 610, 10.1016/j.jalz.2015.06.847 · DOI
- Gold, 2014, Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega-3 trial, American Journal of Respiratory and Critical Care Medicine, 189, D44 COPD
- Kang, 2015, Cognitive substudy of the vitamin d and omega-3 trial (vital-cog): design of a large randomized trial of omega-3 and vitamin d supplements in relation to cognitive change, Alzheimer's & Dementia, 1, 608, 10.1016/j.jalz.2015.06.843 · DOI
- Manson, 2010, Vitamin D and cancer and cardiovascular disease: ready for prime time?, Menopause, 17, 1215
- Abdelhamid, 2017, Polyunsaturated fatty acids for musculoskeletal health and functional status in older adults, PROSPERO, www.crd.york.ac, CRD42017079211
- Hanson, 2017, Dietary polyunsaturated fat for prevention and treatment of depression and anxiety, PROSPERO, www.crd.york.ac, CRD42017056092
- Higgins JP Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Jimoh, 2017, Dietary polyunsaturated fat for prevention and treatment of neurocognitive disorders, PROSPERO, www.crd.york.ac, CRD42017019049
- Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
- Liem, 1997, Dioxins: Chemical Analysis, Exposure and Risk Assessment
- Mariani, 2013, N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials, Journal of the American Heart Association, 2, e005033, 10.1161/JAHA.112.005033 · DOI
- Thorpe, 2017, Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease, PROSPERO, www.crd.york.ac, CRD42017068704
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Lichtenstein, A. H., Appel, L. J., Vadiveloo, M., Hu, F. B., Kris-Etherton, P. M., Rebholz, C. M., Sacks, F. M., Thorndike, A. N., Van Horn, L., Wylie-Rosett, J., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001031 · Cited by 1,065
Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., et al. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.03.016 · Cited by 843
Metadata
- Authors
- Abdelhamid, A. S., Brown, T. J., Brainard, J. S., Biswas, P., Thorpe, G. C., Moore, H. J., Deane, K. H., AlAbdulghafoor, F. K., Summerbell, C. D., Worthington, H. V., Song, F., & Hooper, L.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2018-11-30
- Volume
- 11
- Pages
- CD003177-CD003177
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W4243760090
- Cited by
- 405
- References
- 443
- FWCI
- 38.20
- Type
- journal article
- Language
- en
- Update notices
- new_version (2020-02-29)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.